QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
QQQ   444.35 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   419.96 (-0.35%)
META   486.13 (-1.57%)
GOOGL   150.76 (-0.07%)
AMZN   180.25 (+0.23%)
TSLA   177.93 (-1.06%)
NVDA   907.75 (+0.58%)
NIO   4.61 (-1.28%)
AMD   182.08 (+1.39%)
BABA   72.48 (+1.24%)
T   17.62 (+0.40%)
F   13.22 (+1.23%)
MU   118.11 (-0.86%)
CGC   9.94 (+4.08%)
GE   175.56 (-2.53%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.52 (+1.43%)
XOM   115.72 (+0.65%)
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

$2.29
+0.02 (+0.88%)
(As of 11:32 AM ET)
Today's Range
$2.26
$2.35
50-Day Range
$2.11
$3.74
52-Week Range
$1.05
$4.04
Volume
1,749 shs
Average Volume
20,093 shs
Market Capitalization
$24.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NEPH stock logo

About Nephros Stock (NASDAQ:NEPH)

Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

NEPH Stock Price History

NEPH Stock News Headlines

Nephros Full Year 2023 Earnings: Misses Expectations
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Nephros just upgraded at Benchmark, here's why
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Earnings Outlook For Nephros
Nephros earnings: here's what to expect
What Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?
Nephros Inc NEPH
Benchmark Co. Keeps Their Hold Rating on Nephros (NEPH)
Breakeven On The Horizon For Nephros, Inc. (NASDAQ:NEPH)
Nephros: Q3 Earnings Insights
See More Headlines
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NEPH
Employees
27
Year Founded
N/A

Profitability

Net Income
$-1,580,000.00
Pretax Margin
-11.06%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$0.80 per share

Miscellaneous

Free Float
10,006,000
Market Cap
$24.56 million
Optionable
Not Optionable
Beta
1.34
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Robert Banks
    President, CEO & Director
  • Ms. Judy F. Krandel C.F.A. (Age 59)
    Chief Financial Officer
  • Mr. Alfred Vargas
    Director of Operations
  • Brianne McGuire
    Director of Brand, Marketing & Business Development
  • Vashone R. Thomas
    Vice President of Quality, Regulatory, & Human Resources
  • Mr. Daron G. Evans M.B.A. (Age 50)
    M.S., Chief Executive Officer of Specialty Renal Products, Inc
    Comp: $300.18k
  • Mr. Greg Lucas
    President of Aether Water Systems
  • Ms. Judy Mazzini
    Controller

NEPH Stock Analysis - Frequently Asked Questions

How have NEPH shares performed in 2024?

Nephros' stock was trading at $3.46 at the beginning of 2024. Since then, NEPH shares have decreased by 34.4% and is now trading at $2.27.
View the best growth stocks for 2024 here
.

Are investors shorting Nephros?

Nephros saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,800 shares, a decline of 64.7% from the February 29th total of 5,100 shares. Based on an average trading volume of 26,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.
View Nephros' Short Interest
.

When is Nephros' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NEPH earnings forecast
.

How were Nephros' earnings last quarter?

Nephros, Inc. (NASDAQ:NEPH) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $3.25 million for the quarter. Nephros had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 18.25%.

Who are Nephros' major shareholders?

Nephros' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wexford Capital LP (35.12%). Insiders that own company stock include Andrew Astor, Robert R Jr Banks, Tom Gwydir and Wesley S Lobo.
View institutional ownership trends
.

How do I buy shares of Nephros?

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NEPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners